Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development LifecycleUnusual Whales·Jul 28 at 10:42 AM
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related DisorderUnusual Whales·Jul 27 at 06:03 AMCAMP-0.58%
ST Landfar plans to acquire 51% equity of Huize Pharmaceutical, which is expected to constitute a significant asset restructuring situationZhitong·Aug 11, 2025 at 09:37 AM000504+2.44%
Overview of the lifting of restrictions on the sale of A-shares | July 10Zhitong·Jul 9, 2025 at 08:01 PM300001+4.12%000504+2.44%
ST Landfar plans to list the sale of a 52% stake in its subsidiary Nanhua HepingZhitong·Jun 18, 2025 at 06:21 AM000504+2.44%
The ST sector strengthened, with over 20 stocks hitting the daily limit upZhitong·May 8, 2025 at 09:20 PM002620+4.19%000504+2.44%
Landfar Bio-medicine: The company's stock trading may be subject to delisting risk warningZhitong·Apr 21, 2025 at 06:17 AM000504+2.44%
Landfar Bio-medicine revised its 2024 performance forecast, expecting a net loss of 19 million to 21 million yuanZhitong·Apr 21, 2025 at 05:29 AM000504+2.44%
Hunan Province held a seminar on the development of the cell industryZhitong·Feb 22, 2025 at 06:48 PM000504+2.44%
Landfar Bio-medicine expects to turn a profit, with a projected net profit of 12.5 million to 15.5 million yuan for the fiscal year 2024, compared to a loss in the previous yearZhitong·Jan 21, 2025 at 05:40 AM000504+2.44%
China's first stem cell therapy drug is on the market! Multiple listed companies respondUSHK News·Jan 2, 2025 at 09:37 PM000504+2.44%300238+3.14%
